Journal
CHILDREN-BASEL
Volume 9, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/children9020295
Keywords
autoimmune hemolytic anemia; warm antibody; hypogammaglobulinemia; rituximab
Categories
Ask authors/readers for more resources
This is a case of a 3-year-old boy with severe and refractory warm antibody autoimmune hemolytic anemia. Despite B-cell recovery, the patient continued to have hypogammaglobulinemia 20 months after receiving rituximab therapy.
We describe a case of a 3-year-old male toddler with a history of severe and refractory warm antibody autoimmune hemolytic anemia (w-AIHA) since early infancy and hypogammaglobulinemia persisting 20 months after rituximab administration (second-line rescue therapy). Specifically, although peripheral blood flow cytometry B-cell population counts signified B-cell recovery following completion of rituximab therapy, IgG levels were barely detectable. Detailed laboratory evaluation did not reveal any humoral or cell-mediated immunity impairment and the patient remained asymptomatic, without any infections or recurrence of w-AIHA. Due to severe hypogammaglobulinemia, he was placed on immunoglobulin replacement therapy (IVIG). The implemented PID (primary immunodeficiency) gene panel identified only variants of uncertain significance (VUS). The aim of this report is to underline the documentation of persisting hypogammaglobulinemia after rituximab despite peripheral blood B-cell reconstitution.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available